Humoral Response to mRNA-1273 SARS-CoV-2 Vaccine in Peritoneal Dialysis Patients: Is Boostering After Six Months Adequate?
In dialysis patients the humoral response to anti-SARS-CoV-2 vaccines is attenuated and rapidly declines over time. However, data on the persistence of the immune response in peritoneal dialysis (PD) patients are scarce, particularly after a third (booster) dose with mRNA-1273 vaccine. In this prosp...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-06-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2022.905798/full |
| _version_ | 1811238088394932224 |
|---|---|
| author | Georg Beilhack Rossella Monteforte Florian Frommlet Roman Reindl-Schwaighofer Robert Strassl Andreas Vychytil |
| author_facet | Georg Beilhack Rossella Monteforte Florian Frommlet Roman Reindl-Schwaighofer Robert Strassl Andreas Vychytil |
| author_sort | Georg Beilhack |
| collection | DOAJ |
| description | In dialysis patients the humoral response to anti-SARS-CoV-2 vaccines is attenuated and rapidly declines over time. However, data on the persistence of the immune response in peritoneal dialysis (PD) patients are scarce, particularly after a third (booster) dose with mRNA-1273 vaccine. In this prospective cohort study, we report anti-SARS-CoV-2 antibody levels in PD patients before and after the third dose of mRNA-1273 vaccine. Six months after the second dose, anti-SARS-CoV-2 antibodies were detected in all patients (n = 34). However, within this time period antibodies substantially declined in 31 of 34 patients (4.5-fold, median = 192 BAU/mL, p = 1.27 × 10–9) and increased in three patients. In accordance with government regulations, a third dose of mRNA-1273 vaccine (50 μg) was given to 27 PD patients 6 months after the second dose which induced a significant increase of anti-SARS-CoV-2 antibody titers (58.6-fold, median = 19405 BAU/mL, p = 1.24 × 10–29). A mixed model analysis showed that a lower Davies Comorbidity Score and a higher GFR were associated with higher antibody titers (p = 0.03 and p = 0.02). The most common adverse events after the third dose were pain at the injection site (77.8%) and fatigue (51.9%). No hospitalizations were reported. In conclusion, 6 months after the second dose of mRNA-1273 vaccine, anti-SARS-CoV-2 antibodies substantially decreased in PD patients, whereas a well-tolerated third dose induced a robust humoral response. Our data suggest that the administration of a booster dose within a shorter interval than 6 months should be considered in PD patients in order to maintain high anti-SARS-CoV-2 antibody levels and assure protection from severe COVID-19 disease. |
| first_indexed | 2024-04-12T12:35:40Z |
| format | Article |
| id | doaj.art-e496755cfcd845abba40aed134f2f51d |
| institution | Directory Open Access Journal |
| issn | 2296-858X |
| language | English |
| last_indexed | 2024-04-12T12:35:40Z |
| publishDate | 2022-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj.art-e496755cfcd845abba40aed134f2f51d2022-12-22T03:32:55ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2022-06-01910.3389/fmed.2022.905798905798Humoral Response to mRNA-1273 SARS-CoV-2 Vaccine in Peritoneal Dialysis Patients: Is Boostering After Six Months Adequate?Georg Beilhack0Rossella Monteforte1Florian Frommlet2Roman Reindl-Schwaighofer3Robert Strassl4Andreas Vychytil5Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, AustriaDivision of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, AustriaCenter for Medical Statistics, Informatics and Intelligent Systems, Medical University of Vienna, Vienna, AustriaDivision of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, AustriaDivision of Clinical Virology, Medical University of Vienna, Vienna, AustriaDivision of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, AustriaIn dialysis patients the humoral response to anti-SARS-CoV-2 vaccines is attenuated and rapidly declines over time. However, data on the persistence of the immune response in peritoneal dialysis (PD) patients are scarce, particularly after a third (booster) dose with mRNA-1273 vaccine. In this prospective cohort study, we report anti-SARS-CoV-2 antibody levels in PD patients before and after the third dose of mRNA-1273 vaccine. Six months after the second dose, anti-SARS-CoV-2 antibodies were detected in all patients (n = 34). However, within this time period antibodies substantially declined in 31 of 34 patients (4.5-fold, median = 192 BAU/mL, p = 1.27 × 10–9) and increased in three patients. In accordance with government regulations, a third dose of mRNA-1273 vaccine (50 μg) was given to 27 PD patients 6 months after the second dose which induced a significant increase of anti-SARS-CoV-2 antibody titers (58.6-fold, median = 19405 BAU/mL, p = 1.24 × 10–29). A mixed model analysis showed that a lower Davies Comorbidity Score and a higher GFR were associated with higher antibody titers (p = 0.03 and p = 0.02). The most common adverse events after the third dose were pain at the injection site (77.8%) and fatigue (51.9%). No hospitalizations were reported. In conclusion, 6 months after the second dose of mRNA-1273 vaccine, anti-SARS-CoV-2 antibodies substantially decreased in PD patients, whereas a well-tolerated third dose induced a robust humoral response. Our data suggest that the administration of a booster dose within a shorter interval than 6 months should be considered in PD patients in order to maintain high anti-SARS-CoV-2 antibody levels and assure protection from severe COVID-19 disease.https://www.frontiersin.org/articles/10.3389/fmed.2022.905798/fullCOVID-19peritoneal dialysisanti-SARS-CoV-2 antibodiesboostermRNA-1273 vaccinespikevax |
| spellingShingle | Georg Beilhack Rossella Monteforte Florian Frommlet Roman Reindl-Schwaighofer Robert Strassl Andreas Vychytil Humoral Response to mRNA-1273 SARS-CoV-2 Vaccine in Peritoneal Dialysis Patients: Is Boostering After Six Months Adequate? Frontiers in Medicine COVID-19 peritoneal dialysis anti-SARS-CoV-2 antibodies booster mRNA-1273 vaccine spikevax |
| title | Humoral Response to mRNA-1273 SARS-CoV-2 Vaccine in Peritoneal Dialysis Patients: Is Boostering After Six Months Adequate? |
| title_full | Humoral Response to mRNA-1273 SARS-CoV-2 Vaccine in Peritoneal Dialysis Patients: Is Boostering After Six Months Adequate? |
| title_fullStr | Humoral Response to mRNA-1273 SARS-CoV-2 Vaccine in Peritoneal Dialysis Patients: Is Boostering After Six Months Adequate? |
| title_full_unstemmed | Humoral Response to mRNA-1273 SARS-CoV-2 Vaccine in Peritoneal Dialysis Patients: Is Boostering After Six Months Adequate? |
| title_short | Humoral Response to mRNA-1273 SARS-CoV-2 Vaccine in Peritoneal Dialysis Patients: Is Boostering After Six Months Adequate? |
| title_sort | humoral response to mrna 1273 sars cov 2 vaccine in peritoneal dialysis patients is boostering after six months adequate |
| topic | COVID-19 peritoneal dialysis anti-SARS-CoV-2 antibodies booster mRNA-1273 vaccine spikevax |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2022.905798/full |
| work_keys_str_mv | AT georgbeilhack humoralresponsetomrna1273sarscov2vaccineinperitonealdialysispatientsisboosteringaftersixmonthsadequate AT rossellamonteforte humoralresponsetomrna1273sarscov2vaccineinperitonealdialysispatientsisboosteringaftersixmonthsadequate AT florianfrommlet humoralresponsetomrna1273sarscov2vaccineinperitonealdialysispatientsisboosteringaftersixmonthsadequate AT romanreindlschwaighofer humoralresponsetomrna1273sarscov2vaccineinperitonealdialysispatientsisboosteringaftersixmonthsadequate AT robertstrassl humoralresponsetomrna1273sarscov2vaccineinperitonealdialysispatientsisboosteringaftersixmonthsadequate AT andreasvychytil humoralresponsetomrna1273sarscov2vaccineinperitonealdialysispatientsisboosteringaftersixmonthsadequate |